Treatment of rheumatoid arthritis with hypoxia inducible factor-1alpha antagonists

• US 20050148496A1
• Filed: 11/24/2004
• Published: 07/07/2005
• Est. Priority Date: 11/26/2003
• Status: Abandoned Application

• Current Assignee: Entelos, Inc. (SilkRoad Inc.)
• Original Assignee: Entelos, Inc. (SilkRoad Inc.)
• Inventors: Defranoux, Nadine, Michelson, Seth G., Hurez, Vincent Jacques, Shoda, Lisl Katharine, Wennerberg, Leif Gustaf
• Application Number:
  US10/997,764
• Publication Number:
  US 20050148496A1
• Time in Patent Office: Days
• US Class Current: 514/16.600
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention encompasses a novel method of treating inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases and their clinical symptoms. The inventors have made the discovery that the activity of HIF-1α, a transcription regulator known to have an effect on some cancers, has a significant impact on the pathophysiology of rheumatoid arthritis. The symptoms of an inflammatory disease, such as rheumatoid arthritis, may be alleviated by administering a compound that inhibits the activity of HIF-1α.

Claims

1. A method of alleviating at least one symptom of rheumatoid arthritis comprising administering a therapeutically effective amount of an antagonist of HIF-1α

activity to a patient having rheumatoid arthritis.

2. The method of claim 1, wherein the antagonist of HIF-1α

activity is a protein.

3. The method of claim 1, wherein the antagonist of HIF-1α

activity is a nucleic acid.

4. The method of claim 3, wherein the nucleic acid is an antisense inhibitor.

5. The method of claim 1, wherein the antagonist of HIF-1α

activity is a small molecule.

6. The method of claim 1, wherein the antagonist decreases HIF-1α

activity by at least 45%.

7. The method of claim 6, wherein the antagonist decreases HIF-1α

activity by at least 85%.

8. The method of claim 7, wherein the antagonist decreases HIF-1α

activity by at least 95%.

9. The method of claim 1, wherein the patient is a methotrexate resistant patient.

10. The method of claim 1, wherein the patient is a TNF-α

blockade nonresponder.

11. A method of decreasing density of synovial cells in a joint comprising administering a therapeutically effective amount of an antagonist of HIF-1α

activity to a patient having a condition associated with abnormally increased synovial cell density.

12-20. -20. (canceled)

21. A method of decreasing cartilage degradation in a joint comprising administering a therapeutically-effective amount of an antagonist of HIF-1α

activity to a patient having a condition associated with an abnormally high rate of cartilage degradation.

22-30. -30. (canceled)

31. A method of decreasing IL-6 concentration in synovial tissue comprising administering a therapeutically effective amount of an antagonist of HIF-1α

activity to a patient having a condition associated with an abnormally high concentration of IL-6 in synovial tissue.

32-40. -40. (canceled)

41. A method of manufacturing a drug for use in the treatment of rheumatoid arthritis comprising:

(a) identifying a compound as useful in the treatment of rheumatoid arthritis by;

(i) comparing an amount of HIF-1α

activity in the presence of the compound with an amount HIF-1α

activity in the absence of the compound; and

(ii) identifying the compound as useful in the treatment of rheumatoid arthritis when the amount of HIF-1α

activity in the presence of the compound is lower than the amount of HIF-1α

activity in the absence of the compound; and

(b) formulating said compound for human consumption.

42-80. -80. (canceled)

81. A method identifying a compound useful in the treatment of rheumatoid arthritis, which method comprises:

(a) comparing an amount of HIF-1α

activity in the presence of the compound with an amount HIF-1α

activity in the absence of the compound; and

(b) selecting the compound as useful in the treatment of rheumatoid arthritis when the amount of HIF-1α

activity in the presence of the compound is lower than the amount of HIF-1α

activity in the absence of the compound.

82. The method of claim 81 for screening a collection of compounds, further comprising repeating steps (a) and (b) for each compound of the collection, wherein at least one compound of the collection is selected as useful for the treatment of rheumatoid arthritis.

83. The method of claim 81, wherein the compound is selected as useful in the treatment of rheumatoid arthritis when the amount of HIF-1α

activity in the presence of the compound is at least 45% lower than the amount of HIF-1α

activity in the absence of the compound.

84. The method of claim 83, wherein the compound is selected as useful in the treatment of rheumatoid arthritis when the amount of HIF-1α

activity in the presence of the compound is at least 85% lower than the amount of HIF-1α

activity in the absence of the compound.

85. The method of claim 84, wherein the compound is selected as useful in the treatment of rheumatoid arthritis when the amount of HIF-1α

activity in the presence of the compound is at least 95% lower than the amount of HIF-1α

activity in the absence of the compound.

86. The method of claim 81, wherein the amount of HIF-1α

activity is measured under hypoxic conditions.

87. The method of claim 81, wherein the amount of HIF-1α

activity is measured by an amount of HIF-1α

bound to a hypoxia-responsive element (HRE).

89. The method of claim 81, wherein the amount of HIF-1α

activity is measured by an amount of transcription from an HIF-1α

-responsive gene.

94. The method of claim 81, wherein the amount of HIF-1α

activity is measured by a process comprising the step of;

(a) comparing an amount of leukocytes that migrate through at least one layer of endothelial cells in the presence of the compound with an amount of leukocytes that migrate through at least one layer of endothelial cells in the absence of the compound; and

wherein the amount of leukocytes that migrate represents the amount HIF-1α

activity.

103. The method of claim 81, wherein a decrease in HIF-1α

activity in the presence of the compound is identified by observing an amount of leukocyte apoptosis in the presence of the compound that is higher than an amount of leukocyte apoptosis in the absence of the compound.

104. The method of claim 103, wherein the leukocytes are macrophages.

108. The method of claim 104, wherein the amount of macrophage apoptosis is measured by a process comprising the steps of:

(1) exposing a population of cells to an inducer of apoptosis in the presence or absence of the compound; and

(2) measuring the percentage of cells in the population having DNA fragmentation wherein the percentage of cells having DNA fragmentation represents the amount of macrophage apoptosis.

113. The method of claim 104, wherein the amount of macrophage apoptosis is measured by a process comprising the steps of:

(1) exposing a population of cells to an inducer of apoptosis in the presence or absence of the compound; and

(2) measuring a percentage of cells in the population expressing phosphatidylserine on the extracellular surface of the cell membrane

wherein the percentage of cells expressing phosphatidylserine on the extracellular surface of the cell membrane represents the amount of macrophage apoptosis.

118. The method of claim 81, wherein the amount of HIF-1α

activity is measured by a process comprising the step of;

(a) comparing an amount of angiogenesis in the presence of the compound with an amount of angiogenesis in the absence of the compound;

wherein the amount of angiogenesis represents the amount HIF-1α

activity.

88. (canceled)

90-93. -93. (canceled)

95-102. -102. (canceled)

105-107. -107. (canceled)

109-112. -112. (canceled)

114-117. -117. (canceled)

119-123. -123. (canceled)

124. A method of alleviating at least one symptom of rheumatoid arthritis, comprising administering an antagonist of HIF-1α

activity and an anti-rheumatic drug to a patient having rheumatoid arthritis.

125. The method of claim 124, wherein the anti-rheumatic drug is a symptom-relieving anti-rheumatic drug.

126. The method of claim 124, wherein the anti-rheumatic drug is a disease-modifying anti-rheumatic drug.

127. The method of claim 124, wherein the anti-rheumatic drug is selected from the group of methotrexate, a TNF-α

antagonist, an interleukin-1 receptor antagonist and a steroid.

128. The method of claim 124, wherein the patient is a methotrexate resistant patient and the anti-rheumatic drug is methotrexate, a TNF-α

antagonist, an interleukin-1 receptor antagonist or a steroid.

129. The method of claim 124, wherein the patient is a TNF-α

blockade resistant patient and the anti-rheumatic drug is a TNF-α

antagonist, an interleukin-1 receptor antagonist or a steroid.

130. The method of claim 129, wherein the patient is a TNF-α

blockade hyperplasia nonresponder.